The focus of Dr. Vadlamudi's research to study the
molecular mechanisms by which steroid hormone estrogen signal in normal and
pathological conditions such as cancer. The biological functions of estrogen
are mediated by estrogen receptors (ERs),
however, their signaling mechanisms are elusive.
His research has been
centered on the identification and characterization of novel coregulator
proteins that modulate ER functions.
Current research interests include: (1)
characterizing the function of ER-coregulators in cancer progression (2)
developing transgenic and knock-out mouse models for ER-coregulators (4)
identifying novel molecular targets for therapeutic intervention (5)
characterizing the role of ER coregulators in neurodegenerative disorders such
as stroke and (6) development of small molecular inhibitors.
Mann M, Zou Y, Chen Y, Brann D, and Vadlamudi RK. PELP1 oncogenic functions involve alternative splicing through PRMT6. Molecular Oncology, 2014, Mar;8(2):389-400.
Nair BC, Krishnan SR, Sareddy GR, Mann M, Xu B, Natarajan M, Hasty, P, Brann D, Tekmal RR and Vadlamudi RK. Proline glutamic acid and leucine rich protein-1 is essential for optimal p53-mediated DNA damage response. Cell Death and Differentiation, 2014 Sep;21(9):1409-18.
Cortez V, Samayoa C, Zamora A, Martinez L, Tekmal RR, Vadlamudi RK. PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma. Cancer Research, 2014 Dec 15;74(24):7395-405. PMID: 25377474.
Krishnan SR, Nair BC, Sareddy GR, Saha Roy S, Natarajan M, Suzuki T, Peng Y, Raj G, and Vadlamudi RK. Novel role of PELP1 in regulating a chemotherapy response in MTp53-expressing TNBC cells. 2015, Breast Cancer Research and Treatment, 2015 Apr;150(3):487-99